The US Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years.

Once-daily ZORYVE cream 0.05% provides rapid and significant clearance of atopic dermatitis anywhere on the body and offers clinicians, parents, and caregivers of children ages 2 to 5 an alternative to steroids that can be used for any duration.

“It is essential to have safe and effective treatments for children, who are often diagnosed with atopic dermatitis at a young age and can live with the condition across their lifetime. Young children often experience widespread disease, affecting large portions of their skin. Although topical steroids have been the standard treatment for years, they are not

See Full Page